CTLA4 and neoplasm: Studies had observed that, cadonilimab has higher avidity of binding than PD-1 or CTLA-4 Antibody on surface with a high density of PD-1 and CTLA-4 (17)and more excellent uptake at the tumor site comparing to PD-1 or CTLA-4 targeting antibody (18).